




IFW

Patent Application
Attorney Docket No. PC11696A

I hereby certify that this correspondence is being deposited as first-class mail with the United States Postal Service, and is addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 1st day of June 2004.

By


(Signature of person transmitting)
A. David Jeran

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Gene Michael Bright :

APPLICATION NO.: 10/766,741 : Examiner:

FILING DATE: January 27, 2004 : Group Art Unit:

TITLE: 5HT7 ANTAGONISTS AND INVERSE :
AGONISTS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).


Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Date:

June 1, 2004

Respectfully submitted,




A. David Joran

Attorney for Applicant(s)

Reg. No. 37,858

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212)733-3381



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC11696A	SERIAL NO. 10/766,741
	APPLICANT Gene Michael Bright	
	FILING DATE January 27, 2004	GROUP

U.S. PATENT DOCUMENTS												
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	FILING DATE IF APPROPRIATE
	US	5	1	6	2	3	3	9	11/10/92	John A. Lowe		
	US	5	2	3	2	9	2	9	8/3/93	Manoj C. Desai		

FOREIGN PATENT DOCUMENTS													
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
													YES NO
	EP	0	4	9	9	3	1	3	11/6/97	EPO			
	EP	0	5	2	0	5	5	5	01/9/99	EPO			
	WO	0	2	2	1	6	7	1	12/10/92	PCT			
	WO	9	3	0	0	3	3	1	01/7/93	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
			Richard A. Glennon, "Serotonin Receptors: Clinical Implications", Neuroscience & Biobehavioral Reviews, 14, pp 35-47, (1990)										
			Yoram Solomon et. al., "A Highly Sensitive Adenylate Cyclase Assay", Analytical Biochemistry, 58, pp 541-48, (1974)										
			B. Kenneth Koe et. al., "Sertraline, 1S,4S-N-Methyl-4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Naphthylamine, a New Uptake Inhibitor with Selectivity for Serotonin", J. Pharmacology & Experimental Therapeutics, 226, pp 686-700, (1983)										

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	